LeCanadian

Top Menu

  • Login
  • Archives
  • Les Actualités
  • Advertising
  • Sexy Pages
  • Contact Us

Main Menu

  • Home
  • Business
  • Entertainment
  • Foodie
  • Headline
  • Health
  • Editorials
  • Lifestyle
  • Sports
  • UFO · Exopolitics
  • City
  • Sexuality
  • Dating
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Login
  • Archives
  • Les Actualités
  • Advertising
  • Sexy Pages
  • Contact Us

logo

Header Banner

LeCanadian

  • Home
  • Business
  • Entertainment
  • Foodie
  • Headline
  • Health
  • Editorials
  • Lifestyle
  • Sports
  • UFO · Exopolitics
  • City
  • Sexuality
  • Dating
  • 7 reasons why online casinos are so popular in Ontario

  • La Commission indépendante soutient le recours de la Cour suprême contre le déni des droits des non-francophones par le Québec

  • Independent Commission endorses Supreme Court of Canada challenge against Quebec’s denial of rights to non-francophones

  • Ottawa International Crafts & Book Expo 2023: An assembly of literary brilliance

  • Diane Descôteaux – Une haïkiste passionnée: Le Salon d’Ottawa

Health
Home›Health›In Rush for Regulatory Approval of COVID Vaccines, Do We Need More Data?

In Rush for Regulatory Approval of COVID Vaccines, Do We Need More Data?

By admin
May 19, 2021
451
0
Share:

In April 2021, Pfizer and Moderna announced efficacy results at the six-month mark from the phase 3 trials of their respective COVID-19 vaccines.

Pfizer CEO Albert Bourla said the company’s data “confirm the favourable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA [Food and Drug Administration].” And on May 7 it formally initiated that application which, if successful, will earn the Pfizer-BioNTech product, BNT162b2, the distinction of becoming the first COVID-19 vaccine approved by the FDA.

Because lest we forget, all COVID-19 vaccines currently in use in the U.S. are available under emergency access only.

The situation is similar in Europe, where four COVID-19 vaccines have been granted “conditional marketing authorisations,” a fast track mechanism that can be used in emergencies. These can be converted into standard “marketing authorisations” pending positive data after authorisation, but this has not yet happened for any COVID-19 vaccine being administered.

As hundreds of millions of people around the world get vaccinated, it may seem like wordsmithing to highlight the fact that none of the COVID-19 vaccines in use are actually “approved.” Through an emergency access mechanism known as Emergency Use Authorisation (EUA), the products being rolled out still technically remain “investigational.” Factsheets distributed to vaccinees are clear: “There is no FDA approved vaccine to prevent COVID-19.”

The approval-authorisation distinction is often misunderstood by the media, even in the scientific press. But it was the focus of much discussion back in September 2020. With large phase III trials by Pfizer and Moderna well under way, and the November U.S. presidential election looming, many worried about political pressure resulting in the rollout of an unsafe or ineffective vaccine.

The FDA had already come under fire, accused of bending to the White House in granting EUAs for two COVID-19 treatments, hydroxychloroquine and convalescent plasma. But those fears largely dissipated when the FDA published a guidance document in early October outlining its expectations for the EUA. According to the document, at least half of a trial’s participants would need to be followed for at least two months. This alone made it all but certain no vaccine could cross the line before the election.

The FDA also said it would want a vaccine at least 50% effective (with a confidence interval reaching no lower than 30%) against a primary endpoint of preventing SARS-CoV-2 infection or COVID-19 disease of any severity — parameters it had previously defined as necessary for approval. Even for non-clinical parameters, like manufacturing quality, the FDA characterised its expectations for the EUA as “very similar” to those for approval.

Six months: enough?

One key difference between EUA and approval (also called “licensure,” and which for vaccines is known as a BLA (Biologics License Application) was the expected length of follow-up of trial participants. Unlike its clear articulation of two months for an EUA, the FDA has not committed to a clear minimum for approval.

Cody Meissner, a professor of paediatrics at Tufts University and member of the FDA’s advisory committee, was curious. “Is it possible to predict or estimate when conditions of safety and efficacy might be satisfied for BLA?” Meissner asked at the agency’s December 10 meeting which had been convened to consider the FDA’s first emergency authorisation for the Pfizer vaccine.

The FDA’s Doran Fink responded: “I couldn’t predict, but I will say that we typically ask for at least six months of follow-up in a substantial number of clinical trial participants to constitute a safety database that would support licensure.”

An approval based on six months of data would represent one of the fastest for a novel vaccine in FDA history. Among the six “first in disease” vaccines approved by the FDA since 2006, pre-licensure pivotal trials were a median of 23 months in duration, according to a recent analysis.

Six months also seems substantially shorter than previously conceptualised expectations. A World Health Organization expert group on COVID-19 vaccines (which included FDA regulators) in August 2020 called for follow-up “until at least month 12, or until an effective vaccine is deployed locally.” Another group, composed of industry and academic authors, similarly wrote in October 2020: “we recommend longer term follow-up of all participants … for at least a year after randomisation.”

On paper, the phase III studies by Pfizer, Moderna, and Janssen are all of two years’ duration. But the FDA’s official position on minimum follow-up before licensure is unclear at best.

In its formal guidance last June, the agency said that for licensure applications, it wanted participants followed for COVID-19 outcomes for “as long as feasible, ideally at least one to two years” after the first injection. But the same document states that safety assessments for “serious and other medically attended adverse events” should be studied “for at least six months after completion of all study vaccinations. Longer safety monitoring may be warranted for certain vaccine platforms.”

Asked to clarify whether its guidance is asking for follow-up of at least six months or one year, a spokesperson told The BMJ: “We do not have any further information beyond what is in the guidance document.”

Post Views: 603
Previous Article

Kansas Man Says 2nd Pfizer Shot Left ...

Next Article

Russell Brand: Is There a ‘Deliberate Attempt’ ...

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

Related articles More from author

  • Health

    Birthday Candles Increase Bacterial Count on Cake

    August 12, 2017
    By admin
  • Health

    My COVID Story: “I got COVID after being fully vaccinated”

    September 27, 2021
    By admin
  • Health

    3 Tricks for controlling your emotions in any situation

    August 17, 2019
    By admin
  • Health

    Study: Coconut oil contains molecules found to be effective against coronavirus

    May 6, 2020
    By admin
  • Health

    Pharmaceuticals deplete your body of magnesium, increasing your risk of disease

    June 21, 2019
    By admin
  • Health

    Norway reviewing deaths of frail and elderly patients vaccinated against Covid-19

    February 8, 2021
    By admin


AWeber Smart Designer




Popupar Articles

  • Week
  • Month

Week

Sorry. No data so far.

Month

  • 7 reasons why online casi... In the ever-evolving landscape of entertainment and lei...

Popular on The Le Canadian

  1. The Independent Canadian Commission on Civil and Human Rights
  2. Ottawa Winter Fest
  3. Ottawa Market
  4. Salon du Livre d'Ottawa
  5. Ottawa Book Expo
  6. AgoraCosmopolitan
  7. Agora Publishing Consortium
  8. Le Journal Canadien
  9. Dominion: Food News
  10. LeCanadian.com
  11. The Ottawa Star
  12. Capitalistocracy.com
  13. Agora Books Author House
  14. First Nations Press
  15. Toronto Digital Flog Newspaper
  16. The Etiquette Show
  17. Ontario People's Front
  18. COVID-19 unvaccinated singles

Recent Posts

  • 7 reasons why online casinos are so popular in Ontario
  • La Commission indépendante soutient le recours de la Cour suprême contre le déni des droits des non-francophones par le Québec
  • Independent Commission endorses Supreme Court of Canada challenge against Quebec’s denial of rights to non-francophones
  • Ottawa International Crafts & Book Expo 2023: An assembly of literary brilliance
  • Diane Descôteaux – Une haïkiste passionnée: Le Salon d’Ottawa
  • Diane Descôteaux – Une haïkiste passionnée: Le Salon d’Ottawa
  • How Canadians can access online casinos through mobile phones
  • Comment gérer un retard de vol ?
  • 5 ways sudoku boosts brain health
  • 10 tips to successfully market your law firm

Most Viewed Posts

  • Automated China –Mass-Producing the Future (61,382)
  • Health: Shampoo Helps Hair Loss Sufferers (57,690)
  • Citizens of Italy unleash mass protests against mandatory vaccination law (39,210)
  • Why Investors are Putting Their Money on High-End Real Estate (37,245)
  • Montréal : le cœur battant de la génération Y (37,086)
  • Une Autre Facette de Richard Lipman : Le Soutien d’un Psychologue à la Fondation Fauna (32,512)
  • Introduction To How And Where You Can Trade CFDs (30,166)
  • Canada’s Property Values Rise, In Spite of Signs of Market Slowdown (21,159)
  • “Not Gonna Write Poems” A Poetry Book by Dr. Michael Lee: Could He Be The Next Shel Silverstein? (17,363)
  • Smoking is Still a Problem in Society – But it’s a Problem That’s Being Addressed (16,158)

Visitors

  • Home
  • Business
  • Entertainment
  • Foodie
  • Headline
  • Health
  • Editorials
  • Lifestyle
  • Sports
  • UFO · Exopolitics
  • City
  • Sexuality
  • Dating